_id

690dad78ccc777a4e85d0a13

Ticker

ALNY

Name

Alnylam Pharmaceuticals Inc

Exchange

NASDAQ

Address

675 West Kendall Street, Cambridge, MA, United States, 02142

Country

USA

Sector

Healthcare

Industry

Biotechnology

Currency

USD

Website

https://www.alnylam.com

Description

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Last Close

412.63

Volume

908163

Current Price

397.55

Change

-3.6546058211957404

Last Updated

2025-11-28T12:07:57.214Z

Image

data:image/webp;base64,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

Ipo Date

2004-05-28T00:00:00.000Z

Market Cap

58806501376

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

0.8459266666666667

Sentiment Sources

30

Rating

4

Target Price

489.0891

Strong Buy

12

Buy

12

Hold

7

Sell

1

Strong Sell

1

Current Quarter

2025-09-30

Revenue

1249026000

Cost Of Revenue

197231000

Gross Profit

1051795000

Operating Expenses

683813000

Operating Income

367982000

Interest Expense

44398000

Pretax Income

238969000

Net Income

251084000

Eps

1.8280863208783529

Dividends Per Share

-

Shares Outstanding

132113818

Income Tax Expense

-12115000

EBITDA

297170000

Operating Margin

29.461516413589468

Total Other Income Expense Net

-129013000

Cash

1490249000

Short Term Investments

1234375000

Receivables

964768000

Inventories

75383000

Total Current Assets

3952811000

Property Plant Equipment

693144000

Total Assets

4851662000

Payables

117591000

Short Term Debt

160446000

Long Term Debt

1040276000

Total Liabilities

4617768000

Equity

233894000

Depreciation

13803000

Change In Working Capital

-204660000

Cash From Operations

325109000

Capital Expenditures

12142000

Cash From Investing

501107000

Cash From Financing

-448348000

Net Change In Cash

376941000

PE

1435.871

PB

233.45061181560877

ROE

107.34948309918168

ROA

5.1752162454845365

FCF

312967000

Fcf Percent

0.25056884324265466

Piotroski FScore

4

Health Score

64

Deep Value Investing Score

4

Defensive Investing Score

5.5

Dividend Investing Score

3

Economic Moat Investing Score

8

Garp Investing Score

6

Growth Investing Score

6

Momentum Investing Score

3

Net Net Investing Score

2.5

Quality Investing Score

9

Value Investing Score

5

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

1249026000

Quarters > 0 > income Statement > cost Of Revenue

197231000

Quarters > 0 > income Statement > gross Profit

1051795000

Quarters > 0 > income Statement > operating Expenses

683813000

Quarters > 0 > income Statement > operating Income

367982000

Quarters > 0 > income Statement > interest Expense

44398000

Quarters > 0 > income Statement > pretax Income

238969000

Quarters > 0 > income Statement > net Income

251084000

Quarters > 0 > income Statement > eps

1.8280863208783529

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

137348000

Quarters > 0 > income Statement > income Tax Expense

-12115000

Quarters > 0 > income Statement > EBITDA

297170000

Quarters > 0 > income Statement > operating Margin

29.461516413589468

Quarters > 0 > income Statement > total Other Income Expense Net

-129013000

Quarters > 0 > balance Sheet > cash

1490249000

Quarters > 0 > balance Sheet > short Term Investments

1234375000

Quarters > 0 > balance Sheet > receivables

964768000

Quarters > 0 > balance Sheet > inventories

75383000

Quarters > 0 > balance Sheet > total Current Assets

3952811000

Quarters > 0 > balance Sheet > property Plant Equipment

693144000

Quarters > 0 > balance Sheet > total Assets

4851662000

Quarters > 0 > balance Sheet > payables

117591000

Quarters > 0 > balance Sheet > short Term Debt

160446000

Quarters > 0 > balance Sheet > long Term Debt

1040276000

Quarters > 0 > balance Sheet > total Liabilities

4617768000

Quarters > 0 > balance Sheet > equity

233894000

Quarters > 0 > cash Flow > net Income

251084000

Quarters > 0 > cash Flow > depreciation

13803000

Quarters > 0 > cash Flow > change In Working Capital

-204660000

Quarters > 0 > cash Flow > cash From Operations

325109000

Quarters > 0 > cash Flow > capital Expenditures

12142000

Quarters > 0 > cash Flow > cash From Investing

501107000

Quarters > 0 > cash Flow > cash From Financing

-448348000

Quarters > 0 > cash Flow > net Change In Cash

376941000

Quarters > 0 > ratios > PE

1.8280863208783529

Quarters > 0 > ratios > PB

233.45061181560877

Quarters > 0 > ratios > ROE

107.34948309918168

Quarters > 0 > ratios > ROA

5.1752162454845365

Quarters > 0 > ratios > FCF

312967000

Quarters > 0 > ratios > Piotroski FScore

4

Quarters > 0 > ratios > fcf Percent

0.25056884324265466

Quarters > 0 > health Score

64

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

773689000

Quarters > 1 > income Statement > cost Of Revenue

142953000

Quarters > 1 > income Statement > gross Profit

630736000

Quarters > 1 > income Statement > operating Expenses

646935000

Quarters > 1 > income Statement > operating Income

-16199000

Quarters > 1 > income Statement > interest Expense

40246000

Quarters > 1 > income Statement > pretax Income

-35358000

Quarters > 1 > income Statement > net Income

-66277000

Quarters > 1 > income Statement > eps

-0.5110968876276257

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

129676000

Quarters > 1 > income Statement > income Tax Expense

30919000

Quarters > 1 > income Statement > EBITDA

18832000

Quarters > 1 > income Statement > operating Margin

-2.0937353381009682

Quarters > 1 > income Statement > total Other Income Expense Net

-19159000

Quarters > 1 > balance Sheet > cash

1113685000

Quarters > 1 > balance Sheet > short Term Investments

1743900000

Quarters > 1 > balance Sheet > receivables

567112000

Quarters > 1 > balance Sheet > inventories

71688000

Quarters > 1 > balance Sheet > total Current Assets

3643699000

Quarters > 1 > balance Sheet > property Plant Equipment

692192000

Quarters > 1 > balance Sheet > total Assets

4566019000

Quarters > 1 > balance Sheet > payables

102393000

Quarters > 1 > balance Sheet > short Term Debt

143620000

Quarters > 1 > balance Sheet > long Term Debt

1026522000

Quarters > 1 > balance Sheet > total Liabilities

4315428000

Quarters > 1 > balance Sheet > equity

250591000

Quarters > 1 > cash Flow > net Income

-66277000

Quarters > 1 > cash Flow > depreciation

13944000

Quarters > 1 > cash Flow > change In Working Capital

50077000

Quarters > 1 > cash Flow > cash From Operations

153730000

Quarters > 1 > cash Flow > capital Expenditures

14293000

Quarters > 1 > cash Flow > cash From Investing

-141381000

Quarters > 1 > cash Flow > cash From Financing

53757000

Quarters > 1 > cash Flow > net Change In Cash

93612000

Quarters > 1 > ratios > PE

-0.5110968876276257

Quarters > 1 > ratios > PB

205.72444261765187

Quarters > 1 > ratios > ROE

-26.44827627488617

Quarters > 1 > ratios > ROA

-1.4515270304394265

Quarters > 1 > ratios > FCF

139437000

Quarters > 1 > ratios > Piotroski FScore

2

Quarters > 1 > ratios > fcf Percent

0.18022357820778118

Quarters > 1 > health Score

26

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

594189000

Quarters > 2 > income Statement > cost Of Revenue

71041000

Quarters > 2 > income Statement > gross Profit

523148000

Quarters > 2 > income Statement > operating Expenses

505071000

Quarters > 2 > income Statement > operating Income

18077000

Quarters > 2 > income Statement > interest Expense

38646000

Quarters > 2 > income Statement > pretax Income

-41596000

Quarters > 2 > income Statement > net Income

-57479000

Quarters > 2 > income Statement > eps

-0.4432508714025726

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

129676000

Quarters > 2 > income Statement > income Tax Expense

15883000

Quarters > 2 > income Statement > EBITDA

11455000

Quarters > 2 > income Statement > operating Margin

3.042297989360288

Quarters > 2 > income Statement > total Other Income Expense Net

-59673000

Quarters > 2 > balance Sheet > cash

1019654000

Quarters > 2 > balance Sheet > short Term Investments

1612568000

Quarters > 2 > balance Sheet > receivables

418035000

Quarters > 2 > balance Sheet > inventories

65581000

Quarters > 2 > balance Sheet > total Current Assets

3268258000

Quarters > 2 > balance Sheet > property Plant Equipment

695917000

Quarters > 2 > balance Sheet > total Assets

4213811000

Quarters > 2 > balance Sheet > payables

97399000

Quarters > 2 > balance Sheet > short Term Debt

127804000

Quarters > 2 > balance Sheet > long Term Debt

1025566000

Quarters > 2 > balance Sheet > total Liabilities

4098376000

Quarters > 2 > balance Sheet > equity

115435000

Quarters > 2 > cash Flow > net Income

-57479000

Quarters > 2 > cash Flow > depreciation

14405000

Quarters > 2 > cash Flow > change In Working Capital

-217046000

Quarters > 2 > cash Flow > cash From Operations

-118314000

Quarters > 2 > cash Flow > capital Expenditures

8970000

Quarters > 2 > cash Flow > cash From Investing

113769000

Quarters > 2 > cash Flow > cash From Financing

44084000

Quarters > 2 > cash Flow > net Change In Cash

53597000

Quarters > 2 > ratios > PE

-0.4432508714025726

Quarters > 2 > ratios > PB

446.59499978342797

Quarters > 2 > ratios > ROE

-49.793390219604106

Quarters > 2 > ratios > ROA

-1.3640621280831058

Quarters > 2 > ratios > FCF

-127284000

Quarters > 2 > ratios > Piotroski FScore

0

Quarters > 2 > ratios > fcf Percent

-0.21421466906994238

Quarters > 2 > health Score

8

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

593166000

Quarters > 3 > income Statement > cost Of Revenue

102817000

Quarters > 3 > income Statement > gross Profit

490349000

Quarters > 3 > income Statement > operating Expenses

595508000

Quarters > 3 > income Statement > operating Income

-105159000

Quarters > 3 > income Statement > interest Expense

38971000

Quarters > 3 > income Statement > pretax Income

-193958000

Quarters > 3 > income Statement > net Income

-83763000

Quarters > 3 > income Statement > eps

-0.6513959094797418

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

128590000

Quarters > 3 > income Statement > income Tax Expense

-110195000

Quarters > 3 > income Statement > EBITDA

-140911000

Quarters > 3 > income Statement > operating Margin

-17.728426781036

Quarters > 3 > income Statement > total Other Income Expense Net

-88799000

Quarters > 3 > balance Sheet > cash

966428000

Quarters > 3 > balance Sheet > short Term Investments

1728076000

Quarters > 3 > balance Sheet > receivables

405308000

Quarters > 3 > balance Sheet > inventories

78509000

Quarters > 3 > balance Sheet > total Current Assets

3295285000

Quarters > 3 > balance Sheet > property Plant Equipment

693932000

Quarters > 3 > balance Sheet > total Assets

4239983000

Quarters > 3 > balance Sheet > payables

88415000

Quarters > 3 > balance Sheet > short Term Debt

154904000

Quarters > 3 > balance Sheet > long Term Debt

1024621000

Quarters > 3 > balance Sheet > total Liabilities

4172895000

Quarters > 3 > balance Sheet > equity

67088000

Quarters > 3 > cash Flow > net Income

-83763000

Quarters > 3 > cash Flow > depreciation

-20546000

Quarters > 3 > cash Flow > change In Working Capital

-74212000

Quarters > 3 > cash Flow > cash From Operations

-94662000

Quarters > 3 > cash Flow > capital Expenditures

9094000

Quarters > 3 > cash Flow > cash From Investing

-52910000

Quarters > 3 > cash Flow > cash From Financing

30997000

Quarters > 3 > cash Flow > net Change In Cash

-133846000

Quarters > 3 > ratios > PE

-0.6513959094797418

Quarters > 3 > ratios > PB

761.9984870617697

Quarters > 3 > ratios > ROE

-124.85541378487956

Quarters > 3 > ratios > ROA

-1.9755503736689508

Quarters > 3 > ratios > FCF

-103756000

Quarters > 3 > ratios > Piotroski FScore

0

Quarters > 3 > ratios > fcf Percent

-0.1749189940084226

Quarters > 3 > health Score

8

Valuation > metrics > PE

1435.871

Valuation > metrics > PB

233.45061181560877

Valuation > final Score

1

Valuation > verdict

6662.6% Overvalued

Profitability > metrics > ROE

107.34948309918168

Profitability > metrics > ROA

6.352036563346945

Profitability > metrics > Net Margin

0.2010238377743938

Profitability > final Score

89

Profitability > verdict

Adequate

Risk > metrics > Debt Equity

19.742994689902265

Risk > metrics > Interest Coverage

8.288256227758007

Risk > final Score

39

Risk > verdict

High

Liquidity > metrics > Current Ratio

14.216852433309235

Liquidity > metrics > Quick Ratio

13.945726647892187

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

20

Prev Valuations > 1

20

Prev Valuations > 2

20

Prev Profitabilities > 0

0

Prev Profitabilities > 1

0

Prev Profitabilities > 2

0

Prev Risks > 0

4

Prev Risks > 1

8

Prev Risks > 2

-5

Prev Liquidities > 0

100

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-14T00:13:09.044Z